natgillin/translations-raw huggingface dataset:
The method of paragraph 6, wherein the sequences that originate from the first chromosome are selected to be less than a specified number of base pairs. 
Postupak prema zahtjevu 5, naznačen time, da su sekvence koje se svrstavaju prema prvom kromosomu, odabrane tako da budu manje nego što je specifični broj temeljnih parova.
The obtained results are compared to those from the isosorbide 5-mononitrate, which is used as reference product. 
Dobiveni rezultati su uspoređeni s rezultatima za izosorbid 5-mononitrat, koji je upotrijebljen kao usporedni proizvod.
Macitentan for use in the prevention or treatment of brain metastases according to claim 1, which use is in combination with both radiotherapy and a cytotoxic chemotherapy agent selected from paclitaxel, temozolomide and a mixture of paclitaxel and temozolomide. 
Macitentan za uporabu u prevenciji ili liječenju metastaza na mozgu u skladu s patentnim zahtjevom 1, naznačen time, da se koristi u kombinaciji s oboma, odnosno radioterapijom i citotoksičnim kemoterapijskim sredstvom odabranim od paklitaksela, temozolomida i smjese paklitaksela i temozolomida.
and R5 taken together with the nitrogen atom to which they are attached form a 3- to 8-membered optionally substituted heterocyclo; 
R'*i R* uzeti zajedno s atomom dušika za koji su pričvršćeni tvore 3- do 8- člani opcionalno supstituirani heterocikil;
The total amount of the at least one dispersing agent added before grinding step c), or before and during step c), or before and during and/or after grinding step c), preferably is from about 0.01 to 1.25 wt %, more preferably 0.05 to 1 wt %, even more preferably 0.1 to 0.7 wt %, most preferably 0.3 to 0.5 wt % based on the dry weight of the mineral material. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da ukupna količina barem jednog sredstva za raspršivanje dodanog prije koraka mljevenja c), ili prije i tijekom koraka c), ili prije i tijekom i/ili nakon koraka mljevenja c), je od oko 0.01 do 1.25 wt%, poželjno 0.05 do 1 wt%, još poželjnije 0.1 do 0.7 wt%, najpoželjnije od 0.3 do 0.5 wt% zasnovano na suhoj masi mineralnog materijala.
Use according to claim 26, wherein said neuropathic pain and migraine pain disorders are selected from the group consisting of allodynia, hyperalgesic pain, phantom pain, neuropathic pain related to diabetic neuropathy, neuropathic pain related to trigeminal neuralgia, and neuropathic pain related to migraine. 
Primjena prema patentnom zahtjevu 22, naznačena time što su neuropatski bol i poremećaji migrenoznog bola izabrani iz grupe koju čine alodinija, hiperalgezija, fantomski bol, neuropatski bol povezan sa dijabetičkom neuropatijom, neuropatski bol povezan sa neuralgijom trigeminusa, i neuropatski bol povezan sa migrenom.
The method of any of claim 36, 38, 39, or 40, wherein the method further comprises treating with a chemotherapeutic agent, radiation, or a cytokine. 
Protutijelo, konjugat ili farmaceutski pripravak za uporabu sukladno patentnom zahtjevu 6 ili 7, naznačeno time, što postupak nadalje sadrži tretman a kemoterapeutskim sredstvom, zračenjem ili citokinom.
The composition for use according to claim 23, wherein the therapeutically effective amount of crenolanib or a salt thereof is administered at least one of continuously, intermittently, systemically, or locally. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 23, pri čemu se terapeutski djelotvorna količina crenolaniba ili njegove soli daje najmanje jednom kontinuirano, naizmjenično, sustavno 1li lokalno.
A pharmaceutical composition comprising the compound according to claim 7 or a salt of said compound and a pharmaceutically acceptable carrier or excipient. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj ili njegovu sol prema zahtjevu 9, i farmaceutski prihvatljivo pomoćno sredstvo.
The pharmaceutical dosage form according to claim 5, which is for oral, intravenous, intraperitoneal, transdermal, intrathecal, intramuscular, intranasal, transmucosal, subcutaneous, or rectal administration. 
Farmaceutski oblik doziranja prema bilo kojem od zahtjeva 8 do 11, naznačen time da je za oralnu, intravensku, intraperitonealnu, transdermalnu, intratekalnu, intramuskularnu, intranazalnu, transmukoznu, potkožnu ili rektalnu primjenu.
Compound as defined in claim 1, or a pharmaceutically acceptable salt thereof, for use in treating a disorder or disease in which aberrant Wnt signaling is implicated in a patient, wherein the disorder or disease is selected from a group consisting of diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis, a mycotic or viral infection, a bone or cartilage disease, Alzheimer's disease, osteoarthritis and cancer. 
Spoj kako je definiran u zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu u liječenju poremećaja ili bolesti u kojima je implicirana nenormalna Wnt signalizacija kod pacijenta, pri čemu je poremećaj ili bolest izabrana iz skupine koju čine dijabetička retinopatija, neovaskularni glaukom, reumatoidni artritis, psorijaza, gljivična ili virusna infekcija, bolest kostiju ili hrskavice, Alzheimerova bolest, osteoartritis 1 karcinom.
The resulting mixture was extracted with diethyl ether (3×200 mL) then the organic layers were combined, washed with brine (100 mL), dried (magnesium sulfate) and the solvent evaporated. 
Dobivenu smjesu ekstrahira se dietil-eterom (3 x 200 ml), organske slojeve se pomiješa, ispere slanom vodom (100 ml), osuši (magnezijev sulfat), a otapalo otpari.
Compounds of Formula Ia or Ib and their salts in hydrate or solvate form are also part of the invention. A preferred compound of formula Ia is e.g. 1-{4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl}-azetidine-3-carboxylic acid (Compound A), or a pharmaceutically acceptable salt or prodrug thereof. 
HR P20141152 T1 PATENTNI ZAHTJEVI Spoj, naznačen time, da je to 1-(4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimin)-etil]-2-etil-benzil)-azetidin-3- karboksilna kiselina, i njegovi derivati N-oksida; i njegove farmakološki prihvatljive soli, njegovi solvati ili hidrati, pri čemu se on upotrebljava u prevenciji, sprečavanju ili liječenju upalnih stanja odabranih od polimiositisa ili dermatomiositisa.
for the preparation of compounds of formula I where A is acetate, reacting the free base with acetic acid; or 
(i) reakciju slobodne baze s octenom kiselinom, za proizvodnju spojeva formule I, gdje A je acetat; ili
Use according to any of claims 2, 3, or 4, wherein the AT2 receptor antagonist is selected from compounds, or pharmaceutically compatible salts thereof, represented by the formula (XI) wherein R7 is selected from a substituted biphenylmethylene group represented by formula (XII): wherein: 
Uporaba prema zahtjevu 1, naznačena time da je antagonist AT2 receptora odabran od spojeva, ili njihovih farmaceutski kompatibilnih soli, prikazanih sa formulom (X): [image] pri čemu: X je odabran od CH ili dušika,
A vaccine composition as defined in claim 13 for use in protecting pigs against enzootic pneumonia, Post-weaning Multisystemic Wasting Syndrome (PMWS) and porcine reproductive and respiratory syndrome. 
Cjepivni pripravak u skladu s patentnim zahtjevom 13, naznačen time što je namijenjen upotrebi u zaštiti prasadi od enzootske pneumonije, sindroma višesistemskog propadanja nakon prekida dojenja (PMWS), te svinjskog reproduktivnog i respiratornog sindroma.
The method of claim 1, wherein the adverse reaction is thrombocytopenia. 
Postupak prema zahtjevu 3, gdje je nuspojava trombocitopenija 3. ili 4. stupnja.
The kit of claim 13, wherein the one or more viral cultures comprise one or more dengue virus cultures. 
Oprema sukladno patentnom zahtjevu 13, gdje jedna ili više kultura virusa sadrži jednu ili više kultura dengue virusa.
Hungarian patent application No. 
Mađarska patentna prijava br.
nitration of a compound of formula (VIII) to give a compound of formula (IX): in which R and R' are as defined above; 
(VIII) u kojem su R 1 R' definirani gore, b) nitriranje spoja formule (VIII) pri čemu nastaje spoj formule (IX): že m
The diluted blend is homogenized for another 0.25-2 hours with high shear mixer. 
- razrijeđena mješavina se homogenizira tijekom 0,25-2 sata, te
A compound or pharmaceutically acceptable salt or prodrug thereof having the structure of formula Ia: wherein: 
HR P20190281 T1 PATENTNI ZAHTJEVI 1. = Spoj koji ima strukturu formule Ia:
slaking the divalent metal ion oxide obtained in step (b) in order to obtain an aqueous suspension of a divalent metal ion hydroxide; 
gašenja oksida dvovalentnog metalnog iona dobiven u koraku (b) kako bi se dobilo vodenu suspenziju hidroksida dvovalentnog metalnog iona;
a step c) of coupling of a compound of formula (V) with a compound of formula R2COCl (VII), in the presence of a base, and 
fazu c) sprezanja spoja formule (V) sa spojem formule R2COCl (VII), u prisutnosti baze, i
Thus, it is not useful to specify an exact effective amount in advance. 
Na taj način, nije korisno unaprijed navesti točnu efikasnu količinu.
The remaining pulp is separated and trapped within the bore 1003 of the juicer 111. 
Zaostala pulpa se odvaja i ostaje unutar zapremine 1003 sokovnika 111.
Thereby, in the conventional manufacture of veneers, logs are decorticated, or "de-barked," then said logs are sawn into halves, thirds, quarters or other parts of a log (so called "flitches") and are subsequently watered, as a rule, for several days at an increased temperature, in order to prepare them for the subsequent cutting to veneer, the so-called slicing. 
Stoga, u konvencionalnoj proizvodnji furnira se s debla uklanja kora ili se ona "skida", tada se navedena debla prepile na pola, na tri dijela, na četiri dijela ili na drukčije dijelove debla (tako zvane "trupce") nakon toga se potope u vodu, kao pravilo, kroz nekoliko dana na povišenoj temperaturi, da bi ih se pripremilo za rezanje koje slijedi radi dobivanja furnira, tako zvano rezanje na kriške.
In particular the invention provides a reconstituted surfactant comprising: a lipid carrier; a polypeptide of at least 20 amino acid residues and no more than 40 amino acid residues having the sequence represented by the general formula (I) (SEQ ID NO: 10): 
Rekonstituirani surfakant koji sadržava smjesu fosfolipida i kombinaciju polipeptidnog analoga proteina SP-C, prirodnog surfakanta, s polpepdidnim analogom proteina SP-B, prirodnog surfakanta, naznačen time da rečeni polipepdini analog prirodnog surfakanta, proteina SP-C, sadržava najmanje 20 aminokiselinskih ostataka a ne više od 40 aminokiselinskih ostataka, a koji imaju sekvenciju predstavljenu općem formulom (1)
A pair of filters 13a such as those shown in Figure 3A disposed with their meshes opposing can also be used, to improve their mechanical pressure resistance characteristics. 
Može se također koristiti jedan par filtara 134, takav kao što su oni koji su prikazani na slici 3A, koji imaju mreže postavljene jednu nasuprot drugoj, da bi se time poboljšala njihova karakteristika otpora na mehanički pritisak.
The metal matrix syntactic foam of claim 12 or 13, wherein the metal alloy is an aluminum alloy. 
Sintaktička pjena s metalnom matricom sukladno patentnom zahtjevu 10 ili 11, pri čemu je ta legura metala neka legura aluminija.
The absorption coefficient a may be measured using methods apparent to those skilled in the art based on the Beer-Lambert law. 
Koeficijent apsorpcije a može se mjeriti tako da se koriste postupci koji su jasni onima koji su stručni u ovom području i koji se temelje na Beer-Lambertovom zakonu.
a replacement at the endogenous mouse k immunoglobulin light chain variable region locus of endogenous mouse k immunoglobulin light chain variable region gene segments with a single human Vk1-39/Jk gene segment or a single human Vk3-20/Jk gene segment, wherein the human gene segment is operably linked to an endogenous mouse k constant gene and wherein the cell lacks an endogenous mouse k immunoglobulin light chain variable region locus that is capable of rearranging and forming a gene that encodes a mouse k variable region; and, 
Uporaba u skladu s patentnim zahtjevom 12, naznačena time, da stanica sadržava: (a) genski odsječak varijabilne regije lakog lanca humanog imunoglobulina koji kodira varijabilnu domenu lakog lanca humanog imunoglobulina izvedenu iz humanog segmenta gena VK1-39JK, pri čemu je genski odsječak varijabilne regije lakog lanca humanog imunoglobulina spojen izravno ili preko povezivača, na genski odsječak nepromjenjive regije lakog lanca humanog imunoglobulina, čime se dobiva gen koji kodira laki lanac humanog imunoglobulina;
phenyl, substituted in ortho-position by R3O- and substituted in para- or meta-position by a substituent selected from methyl or chloro; or 
fenil, supstituiran na orto-poziciji s O- i supstituiran na para-poziciji ili meta-poziciji sa supstituentom odabranim od metil ili kloro; ili
mg Tablets containing 0.5 mg of a compound of the invention calculated as the free base: 
2) Tablete sadrže 0.5 mg spoja naznačenog izumom izračunatog kao slobodna baza:
The liquefied gas treatment system according to claim 7, further comprising boil-off gas consuming means that receives and uses boil-off gas compressed while passing through a part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što dodatno uključuje element za potrošnju otparenog plina, koji prima i upotrebljava otpareni plin, koji se komprimira prilikom prolaska kroz dio od više kompresijskih cilindara (14) koje sadrži kompresor (13).
A MEMS microphone device (1), according to claim 3, characterized in that said protecting screen (4) has a 40 micron diameter thread. 
MEMS mikrofonski uređaj (1), u skladu s patentnim zahtjevom 3. naznačen time što navedeni zaštitni zaslon (4) ima nit promjera 40 um.
Use according to one of the claims 8, 9 or 10 wherein the patient is an individual who shows one, two or more of the following conditions: 
Farmaceutski sastav za uporabu prema zahtjevu 11, 12 ili 13, naznačen time, da je pacijent pojedinac kod kojega se pokazuje jedno, dva ili više sljedećih stanja:
X represents hydrogen, -SO2R6, -(C=O)R8, wherein R6 represents substituted or unsubstituted alkyl or aryl, R8 represents alkoxy, aryloxy, substituted or unsubstituted alkyl or aryl, unsubstituted N-alkylpyrazolyl or N-alkylpyrazolyl substituted on ring by one or more groups selected from methyl, ethyl, methoxyl and ethoxyl. 
X predstavlja vodik, -SO2R6, - (C = O) R8, pri čemu R6 predstavlja supstituirani ili nesupstituirani alkil ili aril, R8 predstavlja alkoksi, ariloksi, supstituirani ili nesupstituirani alkil ili aril, nesupstituirani N-alkilpirazolil ili N-alkilpirazolilil supstituiran na prstena za jednu ili više skupina izabranih između metil, etil, metoksil i etoksil.
The process of claim 1, wherein the residuum hydrocarbon (10) is a vacuum residuum feedstock and the residuum hydroconversion reactor system (13) is operated at: a pressure in the range from about 6.9 MPa (1000 psig) to about 27.6 MPa (4000 psig); 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da je ugljikovodični ostatak (10) ostatak sirovine 1z vakuumskog postupka, a reaktorski sustav hidrokonverzije ostataka (13) radi na: tlaku u rasponu od oko 6,9 MPa (1000 psig) do oko 27,6 MPa (4000 psig);
wherein R′ is hydrogen and R is selected from benzyl, acetyl, benzoyl, trifluoromethanesulfonyl, benzenesulfonyl, p-toluenesulfonyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl and benzyloxycarbonyl optionally substituted on the aromatic ring with up to three substituents selected from halogen, cyano and trifluoromethyl; or R′ is trimethylsilyl and R is tert-butoxycarbonyl; or R and R′ taken together with the nitrogen atom they are linked to form a phthalimido group. 
(Xla) naznačen time da R' jest vodik, a R je odabran od sljedećih: benzil, acetil, benzoil, trifluormetanesulfonil, benzenesulfonil, p-toluenesulfonil, metoksikarbonil, etoksikarbonil, tert-butoksikarbonil, aliloksikarbonil i benziloksikarbonil koji može biti supstituiran na aromatskom prstenu s do trima supstituentima odabrani od sljedećih: halogen, cijano i trifluorometil; ili R* jest trimetilsilil, a R jest tert-butoksikarbonil; ili R 1 R* uzeti zajedno s dušikovim atomom za koji su vezani tvore ftalimido-skupinu.
The receiver of claim 9, wherein the FEC decoder comprises: a de-puncturing means configured to perform de-puncturing on LDPC parity bits; an LDPC decoder configured to LDPC-decode the L1 signaling data and the de-punctured LDPC parity bits; and 
Prijamnik iz patentnog zahtjeva 7, pri čemu prvi FEC dekoder obuhvaća: sredstvo zatvaranja probijanja konfigurirano za zatvaranje probijanja na LDPC paritetnim bitovima;
An antibody that is specific against the MHC/peptide complex of MHC with a peptide selected from the group consisting of SEQ ID No. 4 and 5. 
Antitijelo specifično protiv kompleksa MHC/peptid MHC-a s peptidom koji se sastoji od SEQ ID No. 22. Komplet koji se sastoji od:
A method of preparation of the alkenyl triphenylphosphonium derivative of tamoxifen of the general formula IA according to the claim no. 1 characterised by the fact that ylide generated from alkyl bis(triphenylphosphonium) with the general formula XII 
Način pripreme alkil trifenil fosfonijskih derivata tamoksifena opće formule I prema zahtjevu 1 odlikuje se time, da ilid generirani iz tert-butildimefilsili-oksi-alkil-trifenil fosfonija opće formule II, a. oo
The method as claimed in claimed 1, wherein, a procedure of whitening (35) is subsequently proceeded after said procedure of thread formation (34) for retrieving primary color of said raw austenite 300 series materials. 
Postupak prema zahtjevu 1, naznačen time što postupak izbjeljivanja (35) slijedi nakon spomenutog postupka oblikovanja navoja (34) radi dobivanja prvotne boje sirovog materijala austenita serije 300
is at an increased risk of PML if the biological sample is positive for a JCV antibody; or 
(1) je pod povišenim rizikom od PML ako je biološki uzorak pozitivan na protutijelo protiv JCYV; ili
According to a further embodiment of the present invention, provision is made for the filter element to completely or only partially cover the capsule base. 
Kapsula s porcijom (1) prema jednom od prethodnih zahtjeva, naznačena time da element filtera (7) potpuno ili samo djelomično prekriva osnovicu kapsule (3).
represents a structure of the following formula [4-a]: 
O 2 predstavlja strukturu sa sljedećom formulom [4-a]:
the treatment of tuberculosis; 
(a) liječenju tuberkuloze;
The antibody of claim 3, wherein the reference antibody comprises a variable light chain comprised of the amino acid sequence of SEQ ID NO:5 and a variable heavy chain comprised of the amino acid sequence of SEQ ID NO:7 
Monoklonsko protutijelo u skladu s patentnim zahtjevom 1 ili 2, naznačeno time što dodatno sadrži varijabilni laki lanac, koji ima aminokiselinski slijed kao što je iznijet u SEQ ID NO:5, i varijabilni teški lanac, koji ima aminokiselinski slijed kao što je iznijet u SEQ ID NO:7.
The invention further relates also to processes for producing the pharmaceutical preparation and to the use of the pharmaceutical preparation for the treatment of disorders. 
Izum se nadalje odnosi na postupke izrade farmaceutskog pripravka i na uporabu farmaceutskog pripravka za liječenje poremećaja.
A process for the preparation of a Cinacalcet intermediate of formula (VI) which comprises the step of: 
Postupak pripreme intermedijera sinakalceta formule (VI) [image] koji obuhvaća korak:
The method of claim 7, further comprising, reducing the flux excitation command signal during start-up of the system to substantially zero. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što dodatno uključuje smanjivanje zapovjednog signala za pobudu fluksa prilikom pokretanja sustava praktički do nule.
The composition according to claim 6, comprising a molar ratio of magnesium:potassium:citrate of 5:2:4. 
Sastav usklađen s patentnim zahtjevom 4 sadrži molarni omjer magnezija:kalijatcitrata 5:2:4.
In one specific embodiment, the composition contains at least 90% of the crystalline form II of N-benzoyl-staurosporine with respect to the total weight of the solid N-benzoyl-staurosporine in the composition. 
Spoj prema zahtjevu 5, naznačen time, da pri čemu je najmanje 90 masenih % od spomenute krutine N-benzoil-staurosporina u kristalnom obliku II.
The method according to any one of claims 1 to 12, wherein the size of the fibrin pellet is at most 1/10 of the initial sample volume. 
Postupak prema patentnom zahtjevu 10, naznačen time što veličina fibrinske pelete iznosi najviše 1/10 početnog volumena uzorka.
The peptide according to claim 1 or 2, wherein said peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1, pri čemu peptid uključuje nepeptidne veze.
A process for manufacturing a film of ultra-high molecular weight polyolefin comprising the steps of 
PATENTNI ZAHTJEVI Postupak proizvodnje filma od poliolefina ultra-visoke molekularne težine, a koji obuhvaća korake
a non-functional integrase, and 
(a) ne-funkcionalnu integrazu, i
The tornado yoyo according to claim 1, wherein a protruding axle (33) configured to be held by a player or be plucked by a yo-yo string protrudes outwards from the middle of an outer surface of the rotating cap (3). 
Tornado yo-yo u skladu s patentnim zahtjevom 1, naznačen time, da izbočena osovina (33) konfigurirana tako da je drži igrač ili da je izvučena yo-yo kabelom, strši prema van od sredine vanjske površine svake rotirajuće kapice (3).
The drugless plasmid of claim 4, wherein the native cI promoter comprises a polynucleotide having at least 90% identity to a polynucleotide sequence as set forth in SEQ ID NO:30. 
Soj bakterije domaćina prema bilo kojem od zahtjeva 1 do 5, naznačen time, da bakterijski soj sadrži jednu ili više kopija polinukleotida koji sadrži sekvencu kao što je prikazana u SEQ ID NO:75.
In this covering layers 7, 8 there is accommodated a reinforcement layer 13, 14, which may be a woven mat, netting, mesh or the like, for example a glass or carbon fibre reinforced mesh or non-woven material. 
U ovim pokrovnim slojevima 7, 8 smješten je i sloj za ojačanje 13, 14 koji može biti tkani mat, mreža od vlakana, plastična ili metalna mreža ili nešto slično, na primjer staklenim ili ugljičnim vlaknima ojačana mreža ili netkani materijal.
FIELD OF THE INVENTION The present invention relates to certain tetrazole derivatives, and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example as agonists for the nicotinic acid receptor, RUP25. 
Područje izuma Prikazani izum se odnosi na određene derivate tetrazola, te na njihove farmaceutske prihvatljive soli, koji pokazuju korisna farmakološka svojstva, poput na primjer agonističkog djelovanja prema receptorima nikotinske kiseline, RUP25.
The apparatus of claim 1, wherein, when the selected intra prediction mode is a non-directional mode, the scan pattern is a predetermined scan pattern. The apparatus of claim 1, wherein the quantization unit (130) determines a quantization step size of previous coding block in scan order as the quantization step size predictor of the current coding block when a quantization step size of a left coding block of a current coding block and a quantization step size of an above coding block of the current coding block are unavailable. 
Uređaj prema zahtjevu 1, naznačen time što jedinica za kvantizaciju (130) određuje prosjek od dvije važeće veličine kvantizacijskog koraka od veličine koraka kvantizacije lijeve jedinice kodiranja trenutne jedinice kodiranja, veličina kvantizacijskog koraka gore navedene jedinice kodiranja trenutne jedinice za kodiranje i veličinu koraka kvantizacije prethodne jedinice kodiranja trenutne jedinice kodiranja kao prediktor veličine kvantizacijskog koraka i prenosi razliku između veličine koraka kvantizacije i prediktora veličine kvantizacijskog koraka u jedinici za entropijsko kodiranje (140).